Beam Therapeutics' BEAM-301 Eliminates Starch Supplementation in Two Patients in Early Trial
Bitget2026/10/27 11:09- Beam Therapeutics reported initial Phase 1/2 results for BEAM-301 in six patients with glycogen storage disease type Ia on Oct. 27, 2026.
- Two of three patients receiving 40 mg achieved 15 hours of controlled fasting, eliminating daily starch supplementation at their latest assessments.
- Median fasting tolerance at Day 36 rose from 2.5 to 15 hours with 40 mg, versus 2.9 to 4.3 hours with 20 mg.
- Four of six patients experienced serious treatment-related adverse events; no dose-limiting toxicities occurred.
- Enrollment in the 60 mg cohort is underway; the company plans FDA discussions on a potential approval pathway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Profit surges 7-fold, revenue breaks 100 trillions for the first time: SK hynix (SKHY.US) responds to AI bubble concerns with record-breaking quarterly report
SK Hynix reported an operating profit of 83.3 trillion won for the third quarter, surpassing expectations, and announced shareholder returns of approximately 100 trillion won within the year.
AstraZeneca (AZN.US) CEO hints at entry into cancer vaccines: years of experience with mRNA technology and more updates expected in the coming months
AstraZeneca is considering developing a cancer vaccine, with the CEO stating that the company has already accumulated experience in mRNA technology. Personalized vaccines have reduced the recurrence rate of melanoma by 42%, but cost and production capacity remain obstacles to broader adoption.
Crypto prices
More
